Mr. Qiyu Chen
Mr. Qiyu Chen, Executive Director and Co-CEO of Fosun International
Mr. Chen has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE, 600196.SH；02196.HK), a non-executive director and chairman of Shanghai Henlius (listed on the Hong Kong Stock Exchange, 02696.HK), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange, 01099.HK), a director of Gland Pharma Limited (listed on the BSE Limited and National Stock Exchange of India Limited with stock code GLAND), Sanyuan Foods (listed on the SSE, 600429.SH) and various companies within the Group.
Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, and a member of the 14th Shanghai Standing Committee of the Chinese People's Political Consultative Conference.
Mr. Chen received a bachelor's degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005.
Founded in 1992, Fosun is a global innovation-driven consumer group dedicated to providing high-quality products and services for families around the world in Health, Happiness, Wealth, and Intelligent Manufacturing segments. In 2007, Fosun International Limited was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK). As of 31 December 2022, Fosun International's total assets amounted to RMB 823.1billion. Fosun International ranks No.589 on the 2022 Forbes Global 2000 List, with a MSCI ESG ratina of AA.